thibaut mongon kenvue

Order byBest matchMost fresh

Kenvue, CEO Thibaut Mongon

Digest more

· 1d · on MSN

Kenvue CEO Mongon leaves the consumer health company as it continues its strategic review

Kenvue also said that it is continuing to work with its strategic review committee to explore options for the company.

· 1d · on MSN

Tylenol maker Kenvue ousts CEO amid board's strategic review

Cosmetics Business · 8h

Kenvue ousts CEO and launches strategic review amid struggling sales

· 1d

Kenvue CEO Mongon Stepping Down as Company Continues With Strategic Review

Kenvue says that Thibaut Mongon is stepping down as its CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company.

· 1d

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood

· 1d

Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.

· 9h

Kenvue: New CEO, Watch The Dividend (Rating Downgrade)

High debt load and rising rates strain Kenvue’s free cash flow and dividend sustainability.

SchaeffersResearch.com · 1d

Call Traders Circle Tylenol Parent Amid C-Suite Swap

· 1d

Kenvue appoints Kirk Perry as interim CEO, sees Q2 adjusted EPS of $0.28 to $0.29

Fierce Pharma5h

Consumer health giant Kenvue kicks off CEO transition as sales slip

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is taking big steps in its strategic review that has now resulted in a leadersh | Along with the CEO transition announcement,

Barchart on MSN1d

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Renuncia CEO de Kenvue mientras la empresa sigue con su revisión estratégica

Por MICHELLE CHAPMANEl CEO de Kenvue dejará su cargo mientras el fabricante de las marcas Listerine y Band-Aid continúa con una revisión estratégica de sus negocios. Thibaut

Explore more

Johnson & Johnson

Tylenol